Loading...

MBIO MUSTANG BIO INC US FDA Inspections 8-K Filing

MSTN

MB

MUSTANG BIO INC

(MBIO)

2025 8-K

Pre-Market Approval

Nasdaq Compliance

Share Issuance Approval

Asset Sale Agreement

Share Issuance Approval

Annual Meeting Results

Delisting Notice

Annual Meeting Notice

Warrant Exercise Agreement

Nasdaq Delisting Notice

Asset Purchase Agreement

Securities Purchase Agreement

Agreement for Stock Sale

Delisting Notice

Public Offering

Results of Operations and F...

Workforce Reduction

Re-filing of Joint Voluntar...

Financial Results Announcement

Re-filing of Joint Voluntar...

Appointment of Interim CFO

CFIUS Review for Sale of As...

Management Changes

Clinical Trial Data Present...

Earnings Reports

Announcement of Clinical Tr...

Securities Purchase Agreeme...

Other Special Situation

CFIUS Investigation

Other Special Situation

Earnings Report

Contract Renewal

Annual Meeting Approval

Sale of Worcester Cell Proc...

Earnings Report

Amendment to Sales Agreement

Termination of Loan Agreement

Reverse Stock Split

Earnings Report

Reverse Stock Split

External Links:

On July 7, 2025, Mustang Bio, Inc. announced that the U.S. FDA granted Orphan Drug Designation to its treatment MB-101 for recurrent astrocytomas and glioblastoma.

AI Assistant

MUSTANG BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.